Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Jul 19;26(29):7693–7706. doi: 10.1523/JNEUROSCI.0522-06.2006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2006 Society for Neuroscience 0270-6474/06/267693-14$15.00/0

PMC Copyright notice

Figure 3. — Unaltered dynamic properties of GKAP after pharmacological elimination of PSD-95 from the PSD. A, Immunocytochemistry of 2-bromopalmitate-treated neurons using anti-MAGUK (recognizing PSD-95, SAP97, SAP102, and Chapsyn-110 with similar sensitivity) and anti-PSD-95 antibodies. Scale bar, 5 μm. B, Quantitation of immunocytochemistry shown in A. Treatment with 2-bromopalmitate significantly reduced the amount of PSD-95 and related MAGUK proteins at synapses (∗∗∗p < 0.001). C, Presence of GKAP- and Shank-immunoreactive clusters after 2-bromopalmitate treatment and their association with a marker of excitatory presynaptic structure, vesicular glutamate transporter 1 (VGLUT1). Scale bar, 5 μm. D, FRAP analysis of EYFP-GKAP in 2-bromopalmitate-treated neurons showing unaltered dynamic properties of EYFP-GKAP. Error bars indicate SEM.